Akeso’s new drug application for gumokimab, an IL-17-targeting antibody for plaque psoriasis, has been accepted in China.

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

Eisai and Biogen have secured US Food and Drug Administration approval for a once-monthly intravenous maintenance dosing ...

The US Department of Justice announced Friday that Pfizer has agreed in New York federal court to pay $59.7 million to ...

Obesity-focused Aardvark Therapeutics is hoping to raise $100 million in an initial public offering (IPO), according to a US ...

Swarm Oncology, a biotech developing novel T cell therapies to achieve long-term remission in patients with advanced solid ...

Spanish trade group Farmaindustria has set two objectives in biomedical research for 2025, these being consolidating Spain's ...

Privately-held Swiss biotech AB2 Bio has entered into an option and licensing agreement with Japan’s Nippon Shinyaku, which ...

Swiss pharma giant Roche today announced positive top-line results from year two of the EMBARK trial, a global, randomized, ...

Israel – a country that receives almost half of its research and development investments from foreign capital – is a striking ...

Denmark’s life sciences association, Lif, calls for a stronger political vision and regulatory reforms to advance therapies.

US pharma giant Pfizer on Saturday announced positive results from the Phase III BREAKWATER trial evaluating its Braftovi ...